Isotretinoin: How should it be used?;Isotretinoin: Wie behandelt man richtig?

Hautarzt

Volumn 64, Issue 4, 2013, Pages 263-268

  Thielitz, A ^a,b   Gollnick, H ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Dermatologisches Zentrum im Berufsgenossenschaftlichen Unfallkrankenhaus Hamburg Bergedorf   (Germany)

Author keywords

Acne; Cumulative dose; Mechanism of action; Relapse rate; Side effects

Indexed keywords

ISOTRETINOIN;

ACNE; ARTICLE; DRUG USE; FAMILY HISTORY; HUMAN; INNATE IMMUNITY; RECURRENCE RISK; REMISSION;

ACNE VULGARIS; DERMATOLOGIC AGENTS; DERMATOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; GERMANY; HUMANS; ISOTRETINOIN; PRACTICE GUIDELINES AS TOPIC;

EID: 84877925934     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-012-2467-z     Document Type: Article

References (31)

1. Alhusayen RO, Juurlink DN, Mamdani MM et al (2012) Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol [Epub ahead of print]
2. Borghi A, Mantovani L, Minghetti S et al (2011) Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol 25:1094-1098
3. Crijns HJ, Straus SM, Gispen-de WC, de Jong-van den Berg LT (2011) Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol 164:238-244
4. Crockett SD, Gulati A, Sandler RS, Kappelman MD (2009) A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol 104:2387-2393
5. Cunliffe WJ, Norris JF (1987) Isotretinoin - an explanation for its long-term benefit. Dermatologica 175(Suppl 1):133-137
6. Del Rosso JQ (2012) Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses. J Clin Aesthet Dermatol 5:17-24
7. Dispenza MC, Wolpert EB, Gilliland KL et al (2012) Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 132:2198-2205
8. Ganceviciene R, Zouboulis CC (2010) Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges 8(Suppl 1):S47-S59
9. Jones DH, King K, Miller AJ, Cunliffe WJ (1983) A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol 108:333-343
10. Karadag AS, Ertugrul DT, Tutal E, Akin KO (2010) Short-term isotretinoin treatment decreases insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels: Does isotretinoin affect growth hormone physiology? Br J Dermatol 162:798-802
11. Layton AM, Knaggs H, Taylor J, Cunliffe WJ (1993) Isotretinoin for acne vulgaris - 10 years later: a safe and successful treatment. Br J Dermatol 129:292-296
12. Layton AM, Dreno B, Gollnick HP, Zouboulis CC (2006) A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 20:773-776
13. Lee JW, Yoo KH, Park KY et al (2011) Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 164:1369-1375
14. Lehucher-Ceyrac D, La SP de, Chastang C, Morel P (1999) Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 198:278-283
15. Meigel W, Gollnick H, Wokalek H, Plewig G (1983) Orale Behandlung der Acne conglobata mit 13-cis-Retinsäure. Ergebnisse der deutschen Multizenterstudie nach 24 Behandlungswochen. Hautarzt 34:387-397
16. Melnik BC (2011) Isotretinoin and FoxO1: a scientific hypothesis. Dermatoendocrinol 3:141-165
17. Nast A, Bayerl C, Borelli C et al (2010) S2k-Leitlinie zur Aknetherapie. J Dtsch Dermatol Ges 8(Suppl 2):s1-s59
18. Nast A, Dreno B, Bettoli V et al (2012) European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 26(Suppl 1):1-29. http://www.euroderm.org/images/ stories/guidelines/110913-EU-Acne- Guidelines-conglobata-acne-final.pdf
19. Nelson AM, Cong Z, Gilliland KL, Thiboutot DM (2011) TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells. Br J Dermatol 165:526-533
20. Nelson AM, Zhao W, Gilliland KL et al (2009) Isotretinoin temporally regulates distinct sets of genes in patient skin. J Invest Dermatol 129:1038-1042
21. Papakonstantinou E, Aletras AJ, Glass E et al (2005) Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol 125:673-684
22. Quereux G, Volteau C, N'Guyen JM, Dreno B (2006) Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 212:168-176
23. Rademaker M (2012) Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol [Epub ahead of print]
24. Sardana K, Garg VK (2011) Low-dose isotretinoin in acne vulgaris: a critical review. Br J Dermatol 165:698-700
25. Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ (1993) Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 129:297-301
26. Strauss JS, Rapini RP, Shalita AR et al (1984) Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 10:490-496
27. Sundström A, Alfredsson L, Sjolin-Forsberg G et al (2010) Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 341:c5812
28. Thiboutot D, Gollnick H, Bettoli V et al (2012) Oral isotretinoin and pregnancy prevention programmes. Br J Dermatol 166:466-467
29. Karlsson T, Vahlquist A, Kedishvili N, Torma H (2003) 13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? Biochem Biophys Res Commun 303:273-278
30. White GM, Chen W, Yao J, Wolde-Tsadik G (1998) Recurrence rates after the first course of isotretinoin. Arch Dermatol 134:376-378
31. Hennes R, Mack A, Schell H, Vogt HJ (1984) 13-cis-retinoic acid in conglobata acne. A follow-up study of 14 trial centers. Arch Dermatol Res 276:209-215